Market News & Trends
Catalent Commences Construction of New $20M Expansion to its Clinical Supply Facility in Schorndorf, Germany
Catalent recently announced it has begun construction of a $20-million expansion project at its clinical supply facility in Schorndorf, Germany. A ground-breaking ceremony was recently…
Pharmaceutical Contract Manufacturing Market is Expected to Reach $171.3 Billion
The Pharmaceutical Contract Manufacturing industry is expected to continue to grow in the near future due to a number of factors. The aging population is…
Celanese Announces Agreement With Glaukos Corporation for Sustained-Release Glaucoma Treatment
Celanese Corporation, a global specialty materials and chemical company, recently announced it has entered into an agreement with Glaukos Corporation to supply its VitalDose® Drug Delivery Platform for use as….
QSAM Biosciences Opens Enrollment of the Second Cohort of Patients in its Phase 1 Study of Targeting Metastatic Bone Cancer
QSAM Biosciences Inc. recently announced the opening of enrollment into the second grouping of participants (Cohort 2) after completing Cohort 1 in February in its…
AI Therapeutics Announces Positive Results From Phase 2a Biomarker-Driven Trial of AIT-101 in Patients with C9ORF72 Amyotrophic Lateral Sclerosis
AI Therapeutics, Inc. recently announced positive results from a Phase 2a clinical trial of AIT-101 (LAM-002A) in patients with C9ORF72 amyotrophic lateral sclerosis (ALS). In…
Bora Pharmaceuticals & Celltrion Partner to Expand OSD Capabilities in APAC Market
Bora Pharmaceuticals Co., Ltd. and Celltrion Asia Pacific Pte., Ltd. recently announced their partnership to contract manufacture and commercialize a range of oral dosage form drugs (OSD) across the APAC region…..
RespireRx Pharmaceuticals Establishes Research Collaboration With University College London to Study the Use of AMPAkines for the Treatment of GRIA Disorders
RespireRx Pharmaceuticals Inc. recently announced entering into a material transfer agreement with University College London (UCL) as part of a collaborative research effort involving Dr.…
Lonza & ABL Bio Collaborate in the Development & Manufacture of Bispecific Antibody Product
Lonza recently announced it has an agreement with ABL Bio to support the development and manufacturing of ABL Bio’s new bispecific antibody product….
Zevra Therapeutics Announces Submission of IND for KP1077 in Narcolepsy
Zevra Therapeutics, Inc. recently announced the submission of an Investigational New Drug (IND) application seeking authorization from the US FDA to begin a Phase 1…
Caribou Biosciences Announces FDA Granted Fast Track Designation for Allogeneic CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma
Caribou Biosciences, Inc. recently announced the US FDA has granted Fast Track designation to CB-011, which is being developed for relapsed or refractory multiple myeloma…
Eckert & Ziegler to Supply POINT Biopharma With Actinium-225
Eckert & Ziegler (ISIN DE0005659700, TecDAX) and a subsidiary of POINT Biopharma Global Inc. have signed an agreement on the supply of Actinium-225 (non-carrier-added Ac-225).…
Absci Partners With Bioinformatics Company M2GEN to Accelerate Drug Creation for Oncology
Absci Corporation and M2GEN recently announced a partnership to create new cancer medicines and bring them to market at unprecedented speed. Absci’s generative AI drug creation platform will tap into M2GEN’s clinical and….
Dipharma Expands its Italian R&D Center to Increase its Analytical Services
Dipharma Francis S.r.l. recently announced the completion of the expansion of its Research and Development Center for small molecules at its Headquarters located in Baranzate,…
Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra & PD-1 Inhibitor Tislelizumab for Patients With Solid Tumors
Enlivex Therapeutics Ltd. recently announced a clinical collaboration with BeiGene to evaluate the safety and efficacy of Allocetra, an investigational macrophage-reprogramming cell therapy, in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor, for….
A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases
HCW Biologics Inc. recently published a pivotal scientific paper in Aging Cell titled Immunotherapeutic approach to reduce senescent cells and alleviate senescence-associated secretary phenotype in mice with Dr. Hing C. Wong, the company’s Founder and CEO, as lead and….
Vico Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of VO659 in Huntington's Disease & Spinocerebellar Ataxia Types 1 & 3
Vico Therapeutics B.V. recently announced the first patient has been dosed in a Phase 1/2a clinical study evaluating VO659 for the treatment of Huntington's disease…
Comera Life Sciences Announces Expansion of Patent Portfolio Underlying Core Excipient Technology
Comera Life Sciences Holdings, Inc. recently announced the expansion of its patent portfolio with one new patent granted in South Korea and two Notices of…
WACKER, CordenPharma, LMU & HU Berlin Train Machine Learning Algorithm for the Formulation of RNA Actives
Together with Munich’s Ludwig Maximilian University (LMU) and the Humboldt University of Berlin (HU Berlin), Wacker Chemie AG and CordenPharma International GmbH have launched a…
Omega Therapeutics Announces Clinical Supply Agreement to Evaluate the Combination of OTX-2002 & Atezolizumab in Hepatocellular Carcinoma
Omega Therapeutics, Inc. recently announced a clinical supply agreement with Roche to evaluate OTX-2002, its lead candidate in development for the treatment of MYC-driven hepatocellular…
SCYNEXIS & GSK Announce Exclusive Agreement to Commercialize & Further Develop Novel, First-in-Class Medicine to Treat Fungal Infection
SCYNEXIS, Inc. GSK plc recently announced they have entered into an exclusive license agreement for Brexafemme (ibrexafungerp tablets), a US FDA-approved, first-in-class antifungal for the….
